Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

在全球范围内， 默沙东的Gardasil系列产品的销售额与去年相比下降了11%至23亿美元。默沙东首席执行官Robert Davis在周四举行的第三季度电话会议上指出， 这一下滑是由于中国市场需求减少所致，而这抵消了“几乎所有其他地区”的两位数增长。

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

▎药明康德内容团队编辑mRNA癌症疫苗联合Keytruda治疗更早期肺癌，默沙东/Moderna启动3期临床试验默沙东公司（MSD）与Moderna公司今日宣布启动INTerpath-009试验，这是一项关键性3期临床试验，旨在评估在研个体化新抗原疗 ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

新泽西州拉威市和马萨诸塞州剑桥市 - 默沙东集团（NYSE: MRK）和Moderna, Inc.（Nasdaq: ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

基于此前已获批的9项适应症，近期K药针对围手术期局部晚期头颈鳞癌的KEYNOTE-689研究也取得了积极结果，且默沙东已计划提交该适应症的上市申请。这有望成为Keytruda获批的第10项早期癌症适应症。

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Merck & Co reported stronger-than-expected quarterly earnings thanks to rising Keytruda sales. However, Gardasil's weak ...